|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1B
|
|
pubmed:dateCreated |
2001-4-12
|
|
pubmed:abstractText |
Tamoxifen suppresses insulin-like growth factor-1 (IGF-1) plasma levels in early and advanced breast cancer patients. Relationships between tamoxifen (GH) and IGF-1 are complex and not completely described yet. The present investigation was performed to evaluate the effect of acute and chronic tamoxifen administration on GH response to growth hormone-releasing hormone (GHRH), as well as on IGF-1 serum levels.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
585-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11299809-Aged,
pubmed-meshheading:11299809-Aged, 80 and over,
pubmed-meshheading:11299809-Antineoplastic Agents, Hormonal,
pubmed-meshheading:11299809-Breast Neoplasms,
pubmed-meshheading:11299809-Carcinoma, Ductal, Breast,
pubmed-meshheading:11299809-Chemotherapy, Adjuvant,
pubmed-meshheading:11299809-Combined Modality Therapy,
pubmed-meshheading:11299809-Drug Evaluation,
pubmed-meshheading:11299809-Estrogen Antagonists,
pubmed-meshheading:11299809-Estrogens,
pubmed-meshheading:11299809-Female,
pubmed-meshheading:11299809-Growth Hormone-Releasing Hormone,
pubmed-meshheading:11299809-Human Growth Hormone,
pubmed-meshheading:11299809-Humans,
pubmed-meshheading:11299809-Insulin-Like Growth Factor I,
pubmed-meshheading:11299809-Mastectomy, Modified Radical,
pubmed-meshheading:11299809-Middle Aged,
pubmed-meshheading:11299809-Neoplasm Staging,
pubmed-meshheading:11299809-Neoplasms, Hormone-Dependent,
pubmed-meshheading:11299809-Postmenopause,
pubmed-meshheading:11299809-Progesterone,
pubmed-meshheading:11299809-Tamoxifen,
pubmed-meshheading:11299809-Treatment Outcome
|
|
pubmed:articleTitle |
Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
|
|
pubmed:affiliation |
Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141-Milan, Italy. mario.mandala@ieo.it
|
|
pubmed:publicationType |
Journal Article
|
